Welcome to our dedicated page for Zai Lab SEC filings (Ticker: ZLAB), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Zai Lab Limited filings document the SEC reporting record for its American depositary shares and the governance and financing disclosures of a Cayman Islands biopharmaceutical issuer. Form 8-K reports furnish quarterly and annual operating results, financial-condition updates and clinical or regulatory corporate updates tied to its oncology, immunology, neuroscience and infectious disease programs.
The filing record also includes proxy materials covering annual meeting matters, board governance, executive compensation and equity awards. Material-event reports describe capital-structure and liquidity matters, including working-capital credit arrangements, guarantees for Zai Lab Shanghai and related covenant disclosures, while ADR disclosures distinguish the SEC-registered depositary shares from ordinary shares listed in Hong Kong.
Issuer reported Form 144 notice to sell 50,000 American Depositary Shares. The filing lists an option granted on 08/25/2016 and a planned sale of 50,000 ADS on 05/13/2026 for $960,000.00. The filing also reports multiple ADS dispositions by Ying Du between 03/04/2026 and 04/06/2026, including several blocks of 50,000 ADS and smaller sales that together appear in the reported transaction history.
Zai Lab Limited reported first-quarter 2026 revenue of $99.6 million, with net product revenue of $95.6 million, down 10% year over year, and a net loss of $51.0 million (loss of $0.05 per ordinary share).
Sales declined mainly because ZEJULA revenue fell 39% to $30.0 million after volume-based procurement for generic olaparib, and VYVGART revenue softened following a pricing adjustment tied to NRDL renewal. These pressures were partly offset by strong growth from XACDURO, whose revenue rose to $8.6 million, and continued gains from NUZYRA and OPTUNE.
The company increased research and development spending to $65.6 million, driven by higher clinical trial and licensing costs, while selling, general, and administrative expenses rose modestly to $65.1 million. Zai Lab ended the quarter with $761.3 million in cash, cash equivalents, current restricted cash, and short-term investments and $213.8 million in short-term debt, supporting ongoing late-stage programs and new collaborations highlighted in oncology and immunology.
Zai Lab Limited reported first-quarter 2026 total revenue of $99.6 million, down 6% year over year, as weaker oncology sales offset growth in newer products. Net product revenue was $95.6 million, a 10% decline, mainly from lower ZEJULA and VYVGART sales.
ZEJULA revenue fell to $30.0 million from $49.5 million due to volume-based procurement for a competing generic, while VYVGART slipped to $17.6 million after a pricing adjustment tied to NRDL renewal. XACDURO and NUZYRA grew to $8.6 million and $16.3 million, respectively.
Research and development expenses rose to $65.6 million and SG&A to $65.1 million, leading to a GAAP operating loss of $69.4 million and net loss of $51.0 million, or $0.05 per ordinary share. Zai Lab ended March 31, 2026 with $761.3 million in cash, equivalents, short-term investments, and current restricted cash.
The company highlighted standout intracranial response data for its DLL3-targeting ADC zocilurtatug pelitecan in small cell lung cancer and epNECs, new collaborations with Amgen and Boehringer Ingelheim, advancing atopic dermatitis candidate ZL-1503, and positive Phase 3 data from partners’ programs povetacicept in IgA nephropathy and elegrobart in thyroid eye disease.
Zai Lab Limited is calling its 2026 Annual General Meeting for June 17, 2026, in Shanghai with a concurrent virtual option. Shareholders will vote on re-electing nine directors, appointing KPMG LLP and KPMG as 2026 auditors, and giving the Board authority to set auditor fees.
They will also cast an advisory “say-on-pay” vote on named executive officer compensation. Two key capital authorizations are proposed: a general mandate allowing the Board to issue or resell up to 10% of issued ordinary shares and a separate mandate to repurchase up to 10% of issued ordinary shares, each effective until the 2027 meeting.
Zai Lab Limited is soliciting shareholder votes at its 2026 Annual General Meeting to be held on June 17, 2026, seeking re-election of nine directors, approval of KPMG LLP/KPMG as auditors for the year ending December 31, 2026, and shareholder mandates to issue and repurchase up to 10% of issued ordinary shares.
The record date for voting is April 16, 2026. The proxy materials reference 1,134,128,030 issued ordinary shares as of April 10, 2026, implying a 10% cap equal to 113,412,803 shares for each proposed mandate.
Zai Lab Ltd officer Joshua L. Smiley reported an automatic tax-related sale of company stock. On April 6, 2026, he sold 3,017 American Depositary Shares (ADSs) at $20.448 per ADS to cover taxes due upon vesting of Restricted Share Units. Each ADS represents ten Ordinary Shares of Zai Lab. After this tax-cover transaction, Smiley directly held 117,602 ADSs, indicating he retained a substantial equity position in the company.
Zai Lab Ltd Chief Legal Officer Edmondson Frazor Titus III reported an automatic sale of 1,224 American Depositary Shares (ADSs) of Zai Lab Ltd to cover taxes upon vesting of Restricted Share Units. The ADSs were sold at an average price of $20.448 per ADS on April 6, 2026.
Each ADS represents ten Ordinary Shares of Zai Lab Ltd. Following this tax-related sale, Edmondson Frazor Titus III directly holds 23,366 ADSs. The transaction reflects a routine disposition tied to equity compensation rather than a discretionary open-market trade.
Zai Lab Ltd Chairperson and CEO Ying Du reported an open-market sale of 2,653 American Depositary Shares (ADSs) of the company at a price of $20.448 per ADS. A filing footnote explains these ADSs were sold automatically to cover taxes upon vesting of Restricted Share Units.
After this tax-related sale, Ying Du directly holds 1,122,626 ADSs. Each ADS represents ten ordinary shares of Zai Lab, and the ADSs and ordinary shares are fully fungible.
Zai Lab Ltd Chief Financial Officer Yajing Chen reported an open-market sale of 853 American Depositary Shares (ADSs) of Zai Lab on April 6, 2026 at an average price of $20.448 per ADS. Each ADS represents ten ordinary shares, and the company states its ADSs and ordinary shares are fully fungible, though this report is presented in ADS terms.
According to the disclosure, these ADSs were sold automatically to cover taxes triggered by the vesting of Restricted Share Units, indicating a tax-withholding related transaction rather than a discretionary portfolio decision. After this sale, Chen directly holds 31,705 ADSs, showing that the transaction affects only a small portion of her reported direct holdings.